Unlocking the Alzheimer’s Brain: How Radiological Tools and Biomarkers Hold the Key to Early Diagnosis and Decision-Making
Program DescriptionThe age of disease-modifying therapy in Alzheimer’s disease (AD) is now a reality with two amyloid beta targeting therapies (ATT) now approved. Both agents require early diagnosis and therapeutic initiation to exert their effects.
Category
Format
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Pages